The Implications of Using US-Specific EQ-5D Preference Weights for Cost-Effectiveness Evaluation

Katia Noyes, Andrew W. Dick and Robert G. Holloway
Additional contact information
Katia Noyes: Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York, katia_noyes@urmc.rochester.edu
Andrew W. Dick: Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York, The RAND Corporation, Pittsburgh, Pennsylvania
Robert G. Holloway: Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York, Department of Neurology, University of Rochester School of Medicine, Rochester, New York

Medical Decision Making, 2007, vol. 27, issue 3, 327-334

Abstract: Objective. The objective of this study is to examine the effect of country-specific EQ-5D preference weights on the cost-effectiveness (CE) of initial pramipexole versus levodopa strategy in patients with Parkinson disease (PD). Methods. A total of 301 subjects with PD were randomized to initial pramipexole or levodopa and followed every 3 months over a 4-year period. Subjects' health-related quality of life (HRQOL) was measured using EQ-5D, and their health preferences were calculated using both the UK and US sets of weights. The effectiveness of pramipexole was defined as the additional quality-adjusted life-years (QALY) gained compared to levodopa and was estimated as the area between the treatment-specific HRQOL profiles adjusted for baseline difference. Results. Using the original UK weights, the incremental effectiveness was 0.155 QALYs, which resulted in the incremental CE ratio (ICER) of $42,989/QALY and a probability that pramipexole was cost-effective relative to levodopa of 0.57, 0.77, and 0.82 when a QALY was valued at $50,000, $100,000, and $150,000, respectively. Using the US-specific weights resulted in lower incremental effectiveness (0.062 QALYs), higher ICER ($108,498/QALY), and a lower probability that pramipexole was cost-effective compared to levodopa at any valuation of QALY (0.23 for $50,000, 0.48 for $100,000, and 0.58 for $150,000). Conclusions. Country-specific preference weights in clinical-economic trials might have important effects on estimates of incremental cost-effectiveness. Using US preference weights rather than UK preference weights reduced the probability that pramipexole was cost-effective compared to levodopa.

Keywords: Key words: Parkinson disease; EQ-5D; quality of life; cost-effectiveness; pramipexole; levodopa. (Med Decis Making 2007; 27:327—334) (search for similar items in EconPapers)
Date: 2007
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X07301822 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:27:y:2007:i:3:p:327-334

DOI: 10.1177/0272989X07301822

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().